Summary

The RNA Analysis Transcriptomics Market is experiencing robust growth as advancements in genomic technologies continue to reshape modern healthcare and life sciences research. Transcriptomics, the study of RNA transcripts within a cell or organism, has become essential for understanding gene expression, disease progression, and therapeutic responses. The market is projected to reach US$ 7.4 billion in 2026 and is anticipated to expand to US$ 16 billion by 2033, registering a CAGR of 11.50% during the forecast period. This steady growth reflects the rising demand for precision medicine, increasing research activities, and the rapid evolution of sequencing technologies.

Market Insights

RNA analysis technologies have significantly advanced over the past decade, enabling researchers to gain deeper insights into complex biological systems. Techniques such as RNA sequencing, microarrays, and quantitative PCR are widely adopted across research institutions and pharmaceutical companies. The growing shift toward next-generation sequencing platforms has improved the efficiency, sensitivity, and scalability of transcriptomic studies. Additionally, innovations such as single-cell transcriptomics and spatial transcriptomics are transforming the way researchers analyze cellular diversity and tissue-level gene expression. The integration of advanced computational tools and bioinformatics platforms further supports data interpretation and enhances the overall value of transcriptomics in both research and clinical settings.

Drivers

Several key factors are driving the expansion of the RNA Analysis Transcriptomics Market. The increasing prevalence of chronic and complex diseases, including cancer, neurological disorders, and infectious diseases, has intensified the need for advanced diagnostic and research tools. Transcriptomics enables precise identification of disease-related gene expression patterns, supporting early diagnosis and targeted treatment strategies. Furthermore, the growing emphasis on personalized medicine is accelerating the adoption of RNA-based analysis technologies. Government initiatives and funding programs aimed at promoting genomics research are also contributing to market growth. Technological advancements, particularly in sequencing accuracy and cost efficiency, are making transcriptomics more accessible and widely applicable across various sectors.

Business Opportunity

The market presents considerable opportunities for companies operating in genomics, biotechnology, and healthcare analytics. Increasing demand for high-throughput sequencing solutions and integrated data analysis platforms is encouraging innovation and product development. Emerging economies are offering new growth avenues due to improving healthcare infrastructure and rising investments in research and development. The convergence of transcriptomics with other omics disciplines, such as proteomics and metabolomics, is creating opportunities for comprehensive multi-omics analysis. Additionally, the expansion of clinical applications, including biomarker discovery, drug development, and disease monitoring, is expected to drive long-term market potential. Companies that focus on automation, scalability, and user-friendly technologies are well-positioned to capitalize on these opportunities.

Region Analysis

North America continues to lead the RNA Analysis Transcriptomics Market, supported by strong research funding, advanced healthcare infrastructure, and the presence of major industry players. The United States remains a key contributor, with extensive adoption of cutting-edge genomic technologies. Europe holds a significant share of the market, driven by increasing collaborations among research institutions and supportive government policies. Countries such as Germany, the United Kingdom, and France are actively investing in transcriptomics research. The Asia Pacific region is expected to witness the fastest growth, fueled by expanding biotechnology sectors, rising healthcare expenditure, and increasing awareness of precision medicine. China, Japan, and India are emerging as important markets in the region. Meanwhile, Latin America and the Middle East & Africa are gradually gaining traction, supported by improving research capabilities and healthcare development.

Key Players

• Illumina, Inc.

• Thermo Fisher Scientific Inc.

• Agilent Technologies, Inc.

• QIAGEN N.V.

• Bio-Rad Laboratories, Inc.

• F. Hoffmann-La Roche Ltd.

• Merck KGaA

• 10x Genomics, Inc.

• Oxford Nanopore Technologies plc

• Pacific Biosciences of California, Inc.

• Takara Bio Inc.

• PerkinElmer, Inc.

• Promega Corporation

• NanoString Technologies, Inc.

• Bio-Techne Corporation

Segmentation

By Workflow

• Bulk Transcriptomics

• Single-Cell Transcriptomics

• Spatial Transcriptomics

• Comparative Transcriptomics

By Application

• Oncology

• Infectious Diseases

• Immunology

• Genetic Disorders

• Neurological Disorders

By Geography

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Rna Analysis Transcriptomics Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2026
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. COVID-19 Impact Analysis
2.5. Porter's Five Forces Analysis
2.6. Impact of Russia-Ukraine Conflict
2.7. PESTLE Analysis
2.8. Regulatory Analysis
2.9. Price Trend Analysis
2.9.1. Current Prices and Future Projections, 2025-2033
2.9.2. Price Impact Factors
3. Global Rna Analysis Transcriptomics Market Outlook, 2020 - 2033
3.1. Global Rna Analysis Transcriptomics Market Outlook, by Workflow, Value (US$ Bn), 2020-2033
3.1.1. Bulk Transcriptomics
3.1.2. Single-Cell Transcriptomics
3.1.3. Spatial Transcriptomics
3.1.4. Comparative Transcriptomics
3.2. Global Rna Analysis Transcriptomics Market Outlook, by Application Oncology, Value (US$ Bn), 2020-2033
3.2.1. Infectious Diseases
3.2.2. Immunology
3.2.3. Genetic Disorders
3.2.4. Neurological Disorders
3.3. Global Rna Analysis Transcriptomics Market Outlook, by Region, Value (US$ Bn), 2020-2033
3.3.1. North America
3.3.2. Europe
3.3.3. Asia Pacific
3.3.4. Latin America
3.3.5. Middle East & Africa
4. North America Rna Analysis Transcriptomics Market Outlook, 2020 - 2033
4.1. North America Rna Analysis Transcriptomics Market Outlook, by Workflow, Value (US$ Bn), 2020-2033
4.1.1. Bulk Transcriptomics
4.1.2. Single-Cell Transcriptomics
4.1.3. Spatial Transcriptomics
4.1.4. Comparative Transcriptomics
4.2. North America Rna Analysis Transcriptomics Market Outlook, by Application Oncology, Value (US$ Bn), 2020-2033
4.2.1. Infectious Diseases
4.2.2. Immunology
4.2.3. Genetic Disorders
4.2.4. Neurological Disorders
4.3. North America Rna Analysis Transcriptomics Market Outlook, by Country, Value (US$ Bn), 2020-2033
4.3.1. U.S. Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
4.3.2. U.S. Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
4.3.3. Canada Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
4.3.4. Canada Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
4.4. BPS Analysis/Market Attractiveness Analysis
5. Europe Rna Analysis Transcriptomics Market Outlook, 2020 - 2033
5.1. Europe Rna Analysis Transcriptomics Market Outlook, by Workflow, Value (US$ Bn), 2020-2033
5.1.1. Bulk Transcriptomics
5.1.2. Single-Cell Transcriptomics
5.1.3. Spatial Transcriptomics
5.1.4. Comparative Transcriptomics
5.2. Europe Rna Analysis Transcriptomics Market Outlook, by Application Oncology, Value (US$ Bn), 2020-2033
5.2.1. Infectious Diseases
5.2.2. Immunology
5.2.3. Genetic Disorders
5.2.4. Neurological Disorders
5.3. Europe Rna Analysis Transcriptomics Market Outlook, by Country, Value (US$ Bn), 2020-2033
5.3.1. Germany Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
5.3.2. Germany Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
5.3.3. Italy Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
5.3.4. Italy Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
5.3.5. France Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
5.3.6. France Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
5.3.7. U.K. Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
5.3.8. U.K. Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
5.3.9. Spain Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
5.3.10. Spain Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
5.3.11. Russia Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
5.3.12. Russia Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
5.3.13. Rest of Europe Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
5.3.14. Rest of Europe Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
5.4. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Rna Analysis Transcriptomics Market Outlook, 2020 - 2033
6.1. Asia Pacific Rna Analysis Transcriptomics Market Outlook, by Workflow, Value (US$ Bn), 2020-2033
6.1.1. Bulk Transcriptomics
6.1.2. Single-Cell Transcriptomics
6.1.3. Spatial Transcriptomics
6.1.4. Comparative Transcriptomics
6.2. Asia Pacific Rna Analysis Transcriptomics Market Outlook, by Application Oncology, Value (US$ Bn), 2020-2033
6.2.1. Infectious Diseases
6.2.2. Immunology
6.2.3. Genetic Disorders
6.2.4. Neurological Disorders
6.3. Asia Pacific Rna Analysis Transcriptomics Market Outlook, by Country, Value (US$ Bn), 2020-2033
6.3.1. China Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
6.3.2. China Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
6.3.3. Japan Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
6.3.4. Japan Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
6.3.5. South Korea Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
6.3.6. South Korea Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
6.3.7. India Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
6.3.8. India Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
6.3.9. Southeast Asia Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
6.3.10. Southeast Asia Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
6.3.11. Rest of SAO Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
6.3.12. Rest of SAO Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
6.4. BPS Analysis/Market Attractiveness Analysis
7. Latin America Rna Analysis Transcriptomics Market Outlook, 2020 - 2033
7.1. Latin America Rna Analysis Transcriptomics Market Outlook, by Workflow, Value (US$ Bn), 2020-2033
7.1.1. Bulk Transcriptomics
7.1.2. Single-Cell Transcriptomics
7.1.3. Spatial Transcriptomics
7.1.4. Comparative Transcriptomics
7.2. Latin America Rna Analysis Transcriptomics Market Outlook, by Application Oncology, Value (US$ Bn), 2020-2033
7.2.1. Infectious Diseases
7.2.2. Immunology
7.2.3. Genetic Disorders
7.2.4. Neurological Disorders
7.3. Latin America Rna Analysis Transcriptomics Market Outlook, by Country, Value (US$ Bn), 2020-2033
7.3.1. Brazil Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
7.3.2. Brazil Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
7.3.3. Mexico Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
7.3.4. Mexico Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
7.3.5. Argentina Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
7.3.6. Argentina Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
7.3.7. Rest of LATAM Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
7.3.8. Rest of LATAM Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
7.4. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Rna Analysis Transcriptomics Market Outlook, 2020 - 2033
8.1. Middle East & Africa Rna Analysis Transcriptomics Market Outlook, by Workflow, Value (US$ Bn), 2020-2033
8.1.1. Bulk Transcriptomics
8.1.2. Single-Cell Transcriptomics
8.1.3. Spatial Transcriptomics
8.1.4. Comparative Transcriptomics
8.2. Middle East & Africa Rna Analysis Transcriptomics Market Outlook, by Application Oncology, Value (US$ Bn), 2020-2033
8.2.1. Infectious Diseases
8.2.2. Immunology
8.2.3. Genetic Disorders
8.2.4. Neurological Disorders
8.3. Middle East & Africa Rna Analysis Transcriptomics Market Outlook, by Country, Value (US$ Bn), 2020-2033
8.3.1. GCC Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
8.3.2. GCC Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
8.3.3. South Africa Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
8.3.4. South Africa Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
8.3.5. Egypt Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
8.3.6. Egypt Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
8.3.7. Nigeria Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
8.3.8. Nigeria Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
8.3.9. Rest of Middle East Rna Analysis Transcriptomics Market Outlook, by Workflow, 2020-2033
8.3.10. Rest of Middle East Rna Analysis Transcriptomics Market Outlook, by Application Oncology, 2020-2033
8.4. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Vs Segment Heatmap
9.2. Company Market Share Analysis, 2025
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Illumina, Inc.
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Developments
9.4.2. Thermo Fisher Scientific Inc.
9.4.3. Agilent Technologies, Inc.
9.4.4. QIAGEN N.V.
9.4.5. Bio-Rad Laboratories, Inc.
9.4.6. F. Hoffmann-La Roche Ltd.
9.4.7. Merck KGaA
9.4.8. 10x Genomics, Inc.
9.4.9. Oxford Nanopore Technologies plc
9.4.10. Pacific Biosciences of California, Inc.
9.4.11. Takara Bio Inc.
9.4.12. PerkinElmer, Inc.
9.4.13. Promega Corporation
9.4.14. NanoString Technologies, Inc.
9.4.15. Bio-Techne Corporation
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations